96. クローン病 Crohn disease Clinical trials / Disease details

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

27 trials found

diseases per page:

Showing 1 to 10 of 27 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04233463 (ClinicalTrials.gov)	January 2020	15/1/2020	The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosa ...	The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosa ...	Crohn Disease	Dietary Supplement: Modulen;Drug: Budesonide	Hillel Yaffe Medical Center	NULL	Not yet recruiting	18 Years	70 Years	All	50	N/A	Israel
2	JPRN-jRCT1051190043	20/12/2018	02/09/2019	Safety and efficacy of Budesonideadministration after endoscopic balloon dilation for Crohn's diseas ...	Safety and efficacy of Budesonideadministration after endoscopic balloon dilation for Crohn's diseas ...	Crohn's disease	At the time of resumption of food after endoscopic balloon dilation, patients receive 9mg/day budeso ...	Takehara Tetsuo	Iijima Hideki	Recruiting	20age	Not applicable	Both	15	Phase 2	Japan
3	JPRN-UMIN000031839	2018/04/01	01/04/2018	Safety and efficacy of Budesonideadministration after endoscopic ballon dilation for Crohn disease p ...	Safety and efficacy of Budesonideadministration after endoscopic ballon dilation for Crohn disease p ...	Crohn's disease	At the time of resumption of food, patients recerve 9mg/day budesonideorally for 3 weeks, followed b ...	Osaka University Graduate School of MedicineDepartment of Gastroenterology and Hepatology	Japan Community Health care Organizationi Osaka Hospital, Gastroenterology and HepatologyNational Ho ...	Recruiting	20years-old	Not applicable	Male and Female	15	Not selected	Japan
4	JPRN-jRCTs021200013	28/02/2018	31/07/2020	A comparison between combination therapy of Ustekinumab boosted by Budesonideand monotherapy of Uste ...	A comparison of remission rate at 8 weeks between combination therapy of Ustekinumab and Budesonidea ...	Crohn's disease Crohn's disease;D003424	Ustekinumab monotherapy for 32 weeks.	Moroi Rintao	NULL	Recruiting	>= 18age old	<= 75age old	Both	80	Phase 3	Japan
5	JPRN-UMIN000030884	2018/02/27	20/02/2018	A comparison of remission rate at 8 weeks between combination therapy of Ustekinumab and Budesonidea ...		Crohn's disease	Ustekinumab monotherapy for 32 weeks. Combination of Budesonide and Ustekinumab for 32 weeks.	Tohoku University Hospital, Division of Gastroenterology	NULL	Recruiting	18years-old	75years-old	Male and Female	80	Phase 3	Japan
6	JPRN-JapicCTI-184152	01/9/2017	11/10/2018	Investigation of the safety and efficacy of Budesonide( Zentacort Capsules ) in patients with Crohn' ...	Investigation of the safety and efficacy of Budesonide( Zentacort Capsules ) in patients with Crohn' ...	Crohn's disease	Intervention name : Budesonide ( Zentacort Capsules 3mg ) INN of the intervention : Budesonide Dosage A ...	ZERIA Pharmaceutical Co., Ltd.	NULL	recruiting			BOTH	200	NA	NULL
7	NCT01783106 (ClinicalTrials.gov)	February 1, 2014	31/1/2013	Antibiotics and Hydroxychloroquine in Crohn's	A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and H ...	Crohn's Disease	Drug: Ciprofloxacin;Drug: Doxycycline;Drug: Hydroxychloroquine;Drug: Budesonide	Royal Liverpool University Hospital	National Association for Colitis and Crohn's Disease;National Institute for Health Research, United ...	Completed	18 Years	N/A	All	59	Phase 2	United Kingdom
8	EUCTR2011-003743-22-IT (EUCTR)	01/12/2011	08/03/2012	A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treat ...	A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treat ...	Crohn's Disease MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;Sy ...	Trade Name: Entocort INN or Proposed INN: BUDESONIDE	ASTRAZENECA	NULL	Not Recruiting			Female: yes Male: yes	110	Phase 3	United States;Canada;Germany;Italy
9	EUCTR2008-006957-42-BG (EUCTR)	17/11/2009	21/08/2009	Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy an ...	Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy an ...	Induction of remission in active Crohn´s disease MedDRA version: 12.0;Level: LLT;Classification code ...	Product Name: Budenofalk 9mg gastro-resistant granules Product Code: Budenofalk 9mg gastro-resistant ...	Dr. Falk Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 3	Hungary;Slovakia;Czech Republic;Germany;Bulgaria;Latvia;Lithuania
10	NCT01086553 (ClinicalTrials.gov)	November 2009	12/3/2010	9 mg BudesonideOnce Daily (OD) Versus 3 mg BudesonideThree Times Daily (TID) in Active Crohn's Disea ...	Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy an ...	Crohn´s Disease	Drug: budesonide	Dr. Falk Pharma GmbH	NULL	Completed	18 Years	75 Years	Both	471	Phase 3	Germany

First Previous1 2 3Next Last